| Category | $/Batch | $/Unit | % of DP |
|---|
Drug product (DP) COGS covers all manufacturing costs after the drug substance is produced: formulation with excipients, aseptic filling into containers (vials, pre-filled syringes, or autoinjectors), QC release testing, visual inspection, labeling, secondary packaging, stability testing, and cold chain distribution. DP COGS typically adds 20-40% on top of drug substance COGS and ranges from $30-200 per unit for biologics depending on container format and batch size.
Aseptic filling costs for biologics range from $5,000 to $15,000 per hour of line time, depending on the filling technology. At typical line speeds of 1,000-12,000 units per hour, the fill-finish cost per unit ranges from $0.50 to $15. Pre-filled syringes cost 2-3 times more than vials due to slower line speeds and more expensive container components. Outsourced fill-finish at a CDMO typically runs $30,000-300,000 per batch.
A full QC release testing panel for biologics drug product typically includes: identity (peptide mapping), potency (cell-based bioassay), purity (SEC-HPLC, CE-SDS, icIEF), sterility (USP 71, 14-day test), bacterial endotoxin (LAL), subvisible particulates (USP 788), container closure integrity (CCIT), osmolality, pH, protein concentration (A280), and appearance. The total panel costs $10,000-25,000 per batch with turnaround of 3-4 weeks.
Type I borosilicate glass vials cost $0.15-0.50 per unit as a complete closure system. Pre-filled syringes cost $2.00-5.00 per unit for a complete system in nest-and-tub format. Autoinjector devices add $15-50 per unit on top of the PFS. This container cost difference is the primary reason PFS drug products cost significantly more per unit than vial presentations.
For a typical commercial monoclonal antibody, drug substance (upstream cell culture and downstream purification) represents 60-80% of total COGS, while drug product (fill-finish and packaging) represents 20-40%. The split varies by dose and container: a high-dose mAb in vials has a higher DS fraction, while a low-dose biosimilar in an autoinjector has a higher DP fraction because the device cost dominates.
Lyophilization adds $1.00-8.00 per vial to drug product COGS depending on batch size and cycle length. A typical cycle takes 24-72 hours, which significantly reduces line throughput. It requires additional excipients (mannitol, sucrose, trehalose) and adds a reconstitution step for the end user. Lyophilization is used when the protein is unstable in liquid form and extends shelf life from months to years.